SUMMIT
Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
- Public sites
- 71
- Start date
- Jun 15, 2018
Inova’s Structural Heart/Valve Disease Program evaluates and treats aortic, mitral, tricuspid and pulmonary valve disease, paravalvular leaks, and related structural heart conditions. Care includes minimally invasive catheter-based procedures such as TAVR, MitraClip and transcatheter mitral valve replacement, as well as surgical valve repair and replacement, provided by an integrated team of interventional cardiologists, cardiac surgeons and cardiac imaging specialists.
This description was generated by AI based on public sources. Data Sources and Methodology · Report inaccurate information
Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
EARLY TAVR: Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis
PARTNER 3 Trial: Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis
Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial
Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.
Secondary Mitral Regurgitation Treatment With MitraClip and Assessment by Cardiac Magnetic Resonance
Arlington, VA
Washington, DC
Bethesda, MD